Skip to main content
All lobbying filings

PLASMA PROTEIN THERAPEUTICS ASSOCIATION

PLASMA PROTEIN THERAPEUTICS ASSOCIATION filed a Q2 report for PLASMA PROTEIN THERAPEUTICS ASSOCIATION on August 21, 2025.

Lobbying for PLASMA PROTEIN THERAPEUTICS ASSOCIATION

All filings by PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Everything PLASMA PROTEIN THERAPEUTICS ASSOCIATION has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Aug 21, 2025
Expenses
$125,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Maryland

Official filing document

 Lobbyists on this filing 1
  • DANIEL SEATON New on this filing

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 9

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Medicare/Medicaid

Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.

Health Issues

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Trade (domestic/foreign)

Issues relating to tariffs and the importation of plasma-derived medicines, plasma intermediates, and materials necessary to collect source plasma donations and manufacture plasma derived-medicines.

 Bills named in this filing 2

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem